Skip to main content

Femasys, Inc. (FEMY)

NASDAQ: FEMY · IEX Real-Time Price · USD
6.96 -0.16 (-2.25%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap83.31M
Revenue (ttm)1.25M
Net Income (ttm)n/a
Shares Out2.08M
EPS (ttm)-4.91
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume14,625
Open7.11
Previous Close7.12
Day's Range6.92 - 7.11
52-Week Range6.50 - 13.75
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 10, 2021

About FEMY

Femasys is a biomedical company focused on transforming women’s healthcare by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. As a woman-founded and led company with an expansive, internally created intellectual property portfolio with over 100 patents globally, in-house chemistry, manufacturing and controls, or CMC, and device manufacturing capabilities and proven ability to develop and commercialize products, we believe that we are well-positioned to be...

IndustryMedical Instruments & Supplies
IPO DateJun 18, 2021
CEOKathy Lee-Sepsick
Employees25
Stock ExchangeNASDAQ
Ticker SymbolFEMY
Full Company Profile

Financial Performance

In 2020, Femasys's revenue was $1.04 million, an increase of 11.72% compared to the previous year's $929,064. Losses were -$6.91 million, -38.65% less than in 2019.

Financial Statements

News

Femasys Inc. to Present at The MedTech Conference

ATLANTA, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally in...

4 weeks ago - GlobeNewsWire

Femasys Inc. To Join the Russell Microcap® Index

ATLANTA, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (“Femasys” or the “Company”), a biomedical company developing a suite of product candidates to transform women's healthcare with m...

1 month ago - GlobeNewsWire

Femasys Inc. Announces the Appointment of Edward Evantash, M.D. as Chief Medical Officer

-- Industry veteran with over than two decades of experience in medical affairs to lead clinical and medical affairs at Femasys -- ATLANTA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY)...

1 month ago - GlobeNewsWire

Femasys Inc. Announces First Patient Treated in Pivotal Trial for FemaSeed

First in Class Insemination Treatment for Infertility

3 months ago - GlobeNewsWire

Chardan Acts as Lead Left Bookrunner in Femasys' $34.45 Million IPO

NEW YORK, June 21, 2021 /PRNewswire/ -- Chardan, a global investment bank, today announced that it acted as lead left bookrunner in the successful closing of the $34.45 million IPO of Femasys, Inc. (NAS...

4 months ago - PRNewsWire

Femasys Inc. Announces Pricing of Initial Public Offering

Femasys Inc., a biomedical company focused on transforming women's healthcare by developing novel solutions...

4 months ago - GlobeNewswire

Femasys IPO Registration Document (S-1)

Femasys, Inc. has filed to go public with an IPO on the NASDAQ.

5 months ago - SEC